Synthesis and Antidiabetic Activity of Novel

4-((2,4-Dioxothiazolidin-5-ylidene)methyl)Substituted Benzene Sulphonamide


Kishan D. Patel1*, Chhaganbhai N. Patel2, Grishma M. Patel3

1Shree S. K. Patel College of Pharmaceutical Education & Research, Gujarat, India.

2Shri Sarvajanic Pharmacy College, Gujarat, India.

3K. B. Institute of Pharmaceutical Education & Research, Gujarat, India.

*Corresponding Author E-mail:



A new series of 4-((2,4-dioxathiazolidin-5-ylidine)methyl)substituted benzene sulphonamide was prepared. The purity of the new compounds was checked by TLC and elucidation of their structures was confirmed by IR, 1H-NMR and mass spectroscopy. All the target compounds were evaluated for their in vivo antidiabetic activity on male Wistar rats by Oral Glucose Tolerance Test (OGTT) method using pioglitazone as standard. Amongst all, compound K17 and K18 exhibited more prominent antidiabetic activity. The results were statistically verified for its significance.


KEYWORDS: 2,4-dioxathiazolidin, antidiabetic, OGTT, statistically significant, spectroscopy




The metabolic syndrome (MS) is diagnosed by a cluster of clinical parameters including central obesity, atherogenic dyslipidemia, raised blood pressure and hyperglycemia. Visceral obesity, hepatic steatosis and insulin resistance (IR) have been proposed as unifying mechanisms, yielding a pro-thrombotic and pro-inflammatory state1. Type 2 diabetes mellitus (T2DM) is a long-term disease, characterized by a state of fasting hyperglycemia2. Type 2 or adult onset diabetes is a chronic metabolic disorder defined by high levels of glucose in blood due to non-secretion of insulin. According to recent estimates, the world diabetic population could rise to 300 million by the year 2025 due to contemporary lifestyle and Obesity3-4.


The conventional therapy of type 2 diabetes mellitus has not been satisfactory as it is not successful in treating associated risk factor, which is the major cause of morbidity. A current trend is, therefore, to make the therapy better by choosing appropriate combination of available drugs5. A parallel search for newer drugs is also being made. In recent years considerable activity in the pharmaceutical industry has led to the discovery of several chemical classes of antidiabetic agents. Many patent applications explain the intense interest in this field6.


Numerous examples of non-steroidal inhibitors have been disclosed; these include thiazole based compounds (I)7, sulfonamides (II)11, adamantanyl triazoles and carboxamides among others (Fig. 1) 6,9,10.


Compounds I and II belong to the arylsulfonamido (benzo)thiazoles class of 11β-HSD1 inhibitors7,8. We choose these scaffolds as starting point to design the compounds prepared in this work.



Figure 1: Selected 11β-HSD1 inhibitors and drug design of 4-((2,4-dioxothiazolidin-5-ylidene)methyl)-substituted benzene sulphonamide




Melting points of all compounds were determined in open capillaries and are uncorrected. TLC was performed on microscopic slides (2×7.5cms) coated with Silica-Gel-G and spots were visualized by exposure to iodine vapor. IR spectra of all compounds were recorded in KBr (Merck) on FT-IR 8400S Shimadzu spectrophotometer. Mass spectra were recorded on SHIMADZU LCMS 2010 EV Mass Spectrometer. 1H NMR spectra were obtained on BRUKER Advance-II 400 MHz instrument in DMSO as solvent and chemical shift were measured as parts per million downfield from tetramethylsilane (TMS) as internal standard.



Synthesis of 2,4-thiazolidinedione (3) (Figure 2)

Solution containing Chloroacetic acid (1) (0.6 mol) in 60 mL of water and thiourea (2) (0.6 mol) dissolved in 60 mL of water were placed in 250 mL round-bottomed flask. The mixture was stirred for 15 min., followed by cooling to obtain white precipitates. To the content of the flask 60 mL of conc. HCl was added slowly from dropping funnel. The mixture was refluxed for 6 min. at 250 watt in microwave. On cooling the content of the flask solidified into a cluster of white needles. The product was filtered and washed with water to remove the trace of HCl and dried. The product was recrystallised from ethyl alcohol.


Synthesis of 5-benzylidene 2,4-thiazolidinedione (5) (Figure 2)

To a solution of benzaldehyde (4) (0.25 mol) and 2,4-thiazoidinedione (3) (0.25 mol) in hot glacial acetic acid (50 mL), fused sodium acetate (1.8 g) was added and then it was refluxed for 5 min. in microwave at 200 watt. Upon completion of the reaction, 300 mL of water was added and the precipitate obtained was filtered, washed with water and recrystallized from glacial acetic acid.


Synthesis of 4-((2,4-dioxothiazolidin-5-ylidene)methyl) benzene-1-sulphonyl chloride (7) (Figure 2)

Benzylidene 2,4-thiazolidinedione (5) (0.0388 mol) was placed in a 100 mL round bottom flask equipped with condenser and a dropping funnel. Chlorosulphonic acid (6) (0.155 mol) was added at room temperature using dropping funnel. The reaction was found to be exothermic.  After addition of chlorosulphonic acid was over the reaction mixture was refluxed for 1 hr on a water bath. The reaction mixture was cooled and poured into a crused ice. The product was filtered and dried. The product was recrystallized from ethanol.


Procedure for Synthesis of 4-((2,4-dioxothiazolidin-5-ylidene)methyl)-substituted benzene sulphonamide (9) (Figure 2)

A mixture of 4-((2,4-dioxothiazolidin-5-ylidene)methyl)-benzene-1-sulfonyl chloride (7) (0.01 mol) and appropriate primary amine (8) (0.01 mol) were taken in a beaker and made a homogenous paste. The paste was exposed to microwave irradiation (200 watt) for 2-4 min., at interval of 30 seconds. After the completion of the reaction, ice-cold water was added to the reaction mixture and precipitated solid was separated by filtration, dried and recrystallized from ethanol.



Where Ar = 4-COOHC6H4-, 4-CH3C6H4-, 4-ClC6H4-, 3-NO2C6H4-, 4-OCH3C6H4-, C6H5-, 4-OHC6H4-, 2-CH3C6H4-, 4-NO2C6H4-, 4-FC6H4-


Figure 2: Reaction scheme for synthesis of designed compounds


Reagents and Conditions:

(a) H2O, Conc. HCl, Reflux, Microwave irradiation (250 watt), 6 min.; (b) Glacial acetic acid, Sodium acetate, Reflux, Microwave irradiation (200 watt), 5 min.; (c) Reflux, 1 hr.; (d) Reflux, Microwave irradiation (200 watt), 2-4 min.



In-Vivo Antidiabetic Activity

Oral glucose tolerance test

In-vivo study of synthesized compounds by OGTT

The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose that is the body's main source of energy. OGTT, a test of immense value and sentiment, in favour of using fasting plasma glucose concentration alone was seen as a practical attempt to simplify and facilitate the diagnosis of diabetes. Hyperglycemia is an important factor in the development and progression of the complications of diabetes mellitus.


Anti-diabetic activity

The anti-diabetic activity of newly synthesized 4-((2,4-Dioxothiazolidin-5-ylidene)methyl)Substituted Benzene Sulphonamide derivatives was carried out using Oral glucose tolerance test method.


Method: Oral glucose tolerance test

Animals used: Albino Wistar rat

No. of animals used: 6 (in each group)

Dose of std. drug: 30mg/kg (pioglitazone)

Route of administration: Oral

Group I: normal control group.

Group II: pioglitazone control group (30mg/kg)

Group-III-XII: were treated with synthesized compounds. The synthesized compounds were dissolved in suspension of 1% CMC.



Instruments: Glucometer.

Chemicals: 1% CMC

Standard drug: Pioglitazone (30 mg/kg) aq. solution was prepared using 1% CMC.

Test compounds: Solution of compounds was prepared and administered orally similar to that of standard drug.

Apparatus: feeding needles (for oral dosing), syringes (1ml, 2ml)


Experimental design and procedure

Albino Wistar rats weighing about 200-250 gm were taken for study. Group I served as a normal control group while Group II for pioglitazone control group. Group III-XII was treated with synthesized compounds. Special diets are fed for 30 to 90 days prior to the OGTT. We carry out the OGTT by fasting animals for 18 hours, taking a blood sample from the tail under local anesthesia and then gavaging with glucose solution (3gm/kg) of body weight. Blood samples are taken 30, 60, 90 and 120 minutes after the glucose meal and analyzed for blood glucose with a clinical glucometer. The reference drug and the synthesized compounds were administered orally with oral feeding tube to the rats. OGTT for non-diabetic rats were performed according to the standard method.


Group I stands for normal control group. Group II is treated with pioglitazone (30mg/kg body weight). The synthesized compounds were dissolved 1% CMC in according to 30mg/kg of body weight. Then the solution was administered orally to the glucose fed rats and blood was collected from the rat by cutting the tail. Blood sample was taken in a strip and then measured the glucose concentration level by glucometer and plasma glucose level in mg/dl was being monitored at 0, 30, 60 90, 120 minutes for six rats/group. Data were expressed as Mean ± Standard Error of Mean (SEM). Statistical comparisons were performed by one-way ANOVA followed by Dunnett's Multiple Comparison Test and the values were considered statistically significant when P <0.05.11



Spectra for Synthesis of 4-((2,4-dioxothiazolidin-5-ylidene)methyl)-substituted benzene sulphonamide

4-(4-((2, 4-dioxothiazolidin-5-ylidene)methyl) phenylsulphonamido) benzoic acid (K11):

Mass m/z 405.3 [M+H]+ ; IR (cm-1) 1750 and 1680 (C=O), 3000-3200 (Ar-CH), 1327, 1124 (-SO2), 900 (SO2NH), 3637 (OH); 1H NMR (ppm) d 1.8965(s, 1H, Ar-CH-); d 7.3108(s, 1H, -C=O-NH-C=O); d 7.3320(s, 1H, SO2-NH-Ar); d 7.5155-8.0942(m, 8H, Ar-H); d12.5598 (s, 1H, -COOH)


4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-p-tolylbenzene sulphonamide (K12):

Mass m/z 374.9 [M]+ ; IR (cm-1) 1736 and 1660 (C=O), 3000-3200 (Ar-CH), 1321, 1159 (-SO2), 960 (SO2NH), 2930 (CH Aliphatic); 1H NMR (ppm) d 1.8536(s,1H, Ar-CH-); d 2.5852(s, 3H, Ar-CH3); d 6.9899(s, 1H, -C=O-NH-C=O); d 7.1922(s, 1H, SO2-NH-Ar); d 7.2403-8.0945(m, 8H, Ar-H)


4-((2, 4-dioxothiazolidin-5-ylidene)methyl)- N-(4-chlorophenyl)-benzenesulphonamide (K13):

Mass m/z 394.4 [M]+ ; IR (cm-1) 1754 and 1652 (C=O), 3000-3200 (Ar-CH), 1327, 1170 (-SO2), 970 (SO2NH), 893 (Ar-Cl); 1H NMR (ppm) d 1.8965(s, 1H, Ar-CH-); d 7.3108(s, 1H, -C=O-NH-C=O); d 7.3320(s, 1H, SO2-NH-Ar); d 7.5155-8.0942(m, 8H, Ar-H)


4-((2, 4-dioxothiazolidin-5-ylidene)methyl)-N-(3-nitrophenyl)benzene sulphonamide (K14):

Mass m/z 406.7 [M+H]+; IR (cm-1) 1760 and 1674 (C=O), 3000-3200 (Ar-CH), 1322, 1164 (-SO2), 954 (SO2NH), 1520 (NO2); 1H NMR (ppm) d 1.9657(s, 1H, Ar-CH-); d 7.2474(s, 1H, -C=O-NH-C=O); d 7.3304(s, 1H, SO2-NH-Ar); d 7.4870-8.1112(m, 8H, Ar-H)


4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-(4-methoxyphenyl)benzenesulphonamide (K15): Mass m/z 390.6 [M]+; IR (cm-1) 1754 and 1690 (C=O), 3000-3200 (Ar-CH), 1321, 1163 (-SO2), 962 (SO2NH); 1H NMR (ppm) d 1.9645(s, 1H, Ar-CH-); d 3.7839(s, 3H, -O-CH3); d 6.9809(s, 1H, -C=O-NH-C=O); d 7.0401(s, 1H, SO2-NH-Ar); d 7.2500-8.0795(m, 8H, Ar-H)


4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-phenylbenzenesulphonamide (K16): Mass m/z 360.1 [M]+; IR (cm-1) 1736 and 1660 (C=O), 3000-3200 (Ar-CH), 1321, 1159 (-SO2), 960 (SO2NH); 1H NMR (ppm) d 1.9657(s, 1H, Ar-CH-); d 7.2474(s, 1H, -C=O-NH-C=O); d 7.3128(s, 1H, SO2-NH-Ar); d 7.4870-8.1148(m, 9H, Ar-H)


4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-(4-hydroxyphenyl)benzenesulphonamide (K17): Mass m/z 376.8 [M]+; IR (cm-1) 1770 and 1640 (C=O), 3000-3200 (Ar-CH), 1323, 1126 (-SO2), 935 (SO2NH), 3631 (OH); 1H NMR (ppm) d 1.9499(s, 1H, Ar-CH-); d 5.1922(s, 1H, Ar-OH); d 6.9809(s, 1H, -C=O-NH-C=O); d 7.0401(s, 1H, SO2-NH-Ar); d 7.2500-8.0795(m, 8H, Ar-H)


4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-o-tolylbenzenesulphonamide (K18): Mass m/z 375.5 [M+H]+; IR (cm-1) 1736 and 1660 (C=O), 3000-3200 (Ar-CH), 1321, 1159 (-SO2), 960 (SO2NH), 2930 (CH Aliphatic); 1H NMR (ppm) d 1.8673(s, 1H, Ar-CH-); d 2.5861(s, 3H, Ar-CH3); d 6.9880(s, 1H, -C=O-NH-C=O); d 7.0731(s, 1H, SO2-NH-Ar); d 7.1922-8.4152(m, 8H, Ar-H)


4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-(4-nitrophenyl)benzenesulphonamide (K19): Mass m/z 406.8 [M+H]+; IR (cm-1) 1760 and 1674 (C=O), 3000-3200 (Ar-CH), 1322, 1164 (-SO2), 954 (SO2NH), 1520 (NO2); 1H NMR (ppm) d 1.9543(s, 1H, Ar-CH-); d 7.2448(s, 1H, -C=O-NH-C=O); d 7.3217(s, 1H, SO2-NH-Ar); d 7.4870-8.1121(m, 8H, Ar-H)


4-((2,4-dioxothiazolidin-5-ylidene)methyl)-N-(4-fluorophenyl)benzenesulphonamide (K20): Mass m/z 379.1 [M]+; IR (cm-1) 1754 and 1652 (C=O), 3000-3200 (Ar-CH), 1327, 1170 (-SO2), 970 (SO2NH); 1H NMR (ppm) d 1.8977(s, 1H, Ar-CH-); d 7.3188(s, 1H, -C=O-NH-C=O); d 7.3240(s, 1H, SO2-NH-Ar); d 7.5155-8.0958(m, 8H, Ar-H)


The series of 4-((2,4-dioxothiazolidin-5-ylidene)methyl)-substituted benzene sulphonamides contains 2,4-thiazolidinedione linker ring for binding with receptor site, central sulphonyl benzene ring as a linker and substitutes primary aromaric amines as a effectors region for maintaining lipophilicity of molecule. All the synthesized compounds were characterized by IR, Mass and 1H-NMR spectroscopy and report of them supports the structures of compounds.


Figure 3: Effect of Compounds K11-K20(at 30 mg/kg, Oral) on Glucose Excursion in OGTT of Albino Wistar Rats. Each Bar Represents Mean ± SEM (n=6)



Table 1: Physical properties of 4-((2,4-dioxothiazolidin-5-ylidene)methyl)-substituted benzene sulphonamide


Molecular formula

Mol. Wt.

% Yield


Rf value





























































Mobile Phase= Hexane:Ethyl acetate (8:2)


Figure 4: Effect of Compounds K11-K20 (at 30 mg/kg, Oral) on AUC glucose (120 min*mg/dL) in OGTT of Albino Wistar rats. Each bar represents mean ± SEM (n=6)


Table 2: Effect of Compound K11-K20 (at 30 mg/kg, Oral) on AUC glucose (120 min*mg/dL) in OGTT of Albino Wistar rats.


AUC (0-120 min) glucose

Statistically Significance

Vehicle Control










Compound K11




Not significant

Compound K12





Compound K13




Not significant

Compound K14




Not significant

Compound K15





Compound K16





Compound K17





Compound K18





Compound K19




Not significant

Compound K20




Not significant

Each data set represents mean ± SEM (n=6) and data were analysed by One Way ANOVA followed by Dunnet’s multiple comparison t test where P<0.05 Vs vehicle control group.



All the synthesized compounds were screened for In Vivo anti diabetic activity by Oral Glucose Tolerance Test method against standard reference drug pioglitazone. Upon data shown in table 2 and figure 3 and 4, it can be said that, compounds K17 and K18 substituted with electron releasing 4-hydroxy and 2-methyl groups respectively, on aromatic lipophilic ring have shown most potent antidiabetic activity; while compounds K12, K15 and K16 containing 4-methyl, 4-methoxy and no substitution respectively, on aromatic ring have also shown good antidiabetic activity as compared to standard pioglitazone. It was noted that compounds possessing electron releasing substitution at 2nd and/or 4th position on aromatic ring of lipophilic region shows promising antidiabetic activity. 4-chloro and 4-fluoro substituted compounds K13 and K20 have also shown antidiabetic activity. The remaining compounds K11, K14 and K19 substituted with electron withdrawing 4-carboxyl, 3-nitro and 4-nitro respectively, on aromatic ring have shown less antidiabetic activity as compared to pioglitazone.



Looking at the results, it revealed that compounds containing thiazolidinedione ring have better antidiabetic activity because of structural similarity towards PPARγ receptors. It was also noted that 2,4-thiazolidinediones having more lipophilic moieties have exhibited more potent antidiabetic activity, so it is concluded that 2, 4-thiazolidinedione compounds containing more lipophilic group increases antidiabetic activity.



We are grateful to the management of Shree S. K. Patel College of Pharmaceutical Education and Research for encouragement and providing laboratory facility. We are also thankful to sophisticated analytical instrumentation facility department, Punjab University for analytical support.



1.        G.M. Reaven, Diabetes 1988; 37, 1595-1607.

2.        N.C. Turner, Drug Discovery Today 1996; 1, 103–108.

3.        H. King, R.E. Aubert, W.H. Herman, Diabetes Care 1998; 21, 1414–1431.

4.        D.P. Rotella, J. Med. Chem. 2004; 47, 4111–4112.

5.        M.J. Nanjan,  B.R. Pranshantha, Indian J. Pharm. Sci. 2008; 70, 565-571.

6.        (a) M. Wamil, J.R. Seckl, Drug Discovery Today 2007; 12, 504; (b) M. Wang, Curr. Opin. Invest. Drugs 2006; 7, 319; (c) C. Fotsch, B.C. Askew, J.J. Chen, Expert Opin. Ther. Patents 2005; 15, 289; (d) S.P. Webster, T.D. Pallin, Expert Opin. Ther. Patents 2007; 17, 1407.

7.        T. Barf, J. Vallgarda, R. Emond, C. Haggstrom, G. Kurz, A. Nygren, V. Larwood, E. Mosialou, K. Axelsson, R. Olsson, L. Engblom, N. Edling, Y. Ronquist-Nii, B. Ohman, P. Alberts, L. Abrahmsen, J. Med. Chem. 2002; 45, 3813.

8.        X. Su, N. Vicker, D. Ganeshapillai, A. Smith, A. Purohit, M. Reed, Mol. Cell Endocrinol. 2006; 248, 214.

9.        S. Olson, S.D. Aster, K. Brown, L. Carbin, D.W. Graham, A. Hermanowski-Vosatka, Bioorg. Med. Chem. Lett. 2005; 15, 4359.

10.     C.D. Boyle, T.J. Kowalski, L.L. Zhang, Ann. Rep. Med. Chem. 2006; 41, 127.

11.     B. Bhatt, S. Ponnala, D. Sahu, P. Tiwari, A. Srivastava,, Bioorganic and Medicinal Chemistry 2004; 12, 5857-5864.




Received on 16.02.2015          Accepted on 03.03.2015        

© Asian Pharma Press All Right Reserved

Asian J. Res. Pharm. Sci. 5(1): Jan.-March 2015; Page 1-7

DOI: 10.5958/2231-5659.2015.00001.6